by | Apr 29, 2025 | Lupus Foundation of America, News & Events
In a new study, researchers evaluated the potential relationship between disordered eating attitudes and nutritional status in women with systemic lupus erythematosus (SLE). The cross-sectional study consisted of 46 premenopausal women between the ages of 18 and 40...
by | Apr 28, 2025 | Lupus Foundation of America, News & Events
Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819. This designation signifies that a therapy meets specific requirements...
by | Apr 24, 2025 | Lupus Foundation of America, News & Events
A new study published in The Journal of the American Heart Association provides insights to improve cardiovascular disease (CVD) risk prediction in women with systemic lupus erythematosus (SLE). CVD is a significant concern for individuals with SLE, accounting for...
by | Apr 24, 2025 | Lupus Foundation of America, News & Events
A new study explores the relationship between frailty, the proportion of health deficits present in an individual, as measured by the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI), and future health-related quality of life (HRQoL) in...
by | Apr 22, 2025 | Lupus Foundation of America
Allogene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational allogeneic CAR-T therapy, ALLO-329, for three autoimmune conditions: active refractory moderate-to-severe systemic lupus...
by | Apr 21, 2025 | Lupus Foundation of America, News & Events
In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of cutaneous lupus erythematosus disease (CLE, lupus skin disease). The...
